The First International Symposium on Pheochromocytoma ... it is not currently cost effective to test every gene in every patient. Consideration of tumor location, presence of multiple tumors ...

In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

Recently case reports have appeared in which both benzodioxane and dibenamine were effective in lowering the blood pressure to normal in a patient subsequently proved to have a pheochromocytoma.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Patients with MEN-1 may develop tumors in the pancreas, which then release excess hormones. MEN type 2A can cause medullary thyroid cancer, hyperparathyroidism, and pheochromocytoma. MEN type 2B is a ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

As outlined by patient representatives at the ISP ... remains recommended for all cases of pheochromocytoma or paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.